Abstract
Platinum drugs are employed in a wide range of solid tumors, and represent the mainstay of the first-line therapy of ovarian carcinoma. Although cisplatin has shown efficacy in the treatment of different types of tumors including ovarian carcinoma, resistance to treatment is a major limitation. At present, one of the most clinically relevant cisplatin analogues is the mononuclear compound oxaliplatin, which has shown activity and a favorable pharmacological profile in clinical therapy. In cellular models, oxaliplatin exhibits activity in some cell lines with acquired resistance to cisplatin, whereas in other models cross-resistance with cisplatin is observed. In general, oxaliplatin and cisplatin exhibit different pattern of cytotox-icity, indicating differences in drug-DNA interaction and/or cellular response or detoxification. Thus, differences in the influx or efflux mechanisms for these drugs could contribute to their unique patterns of clinical activity and at least in part to sensitivity profiles. Impaired drug accumulation has been recognized over the years as a frequent feature of cells resistant to cisplatin and more recently as an alter ation of oxaliplatin-resistant models. The present chapter reviews recent studies on the molecular alterations of cells resistant to oxaliplatin, with particular reference to accumulation defects and will revisit recent literature in an attempt to describe a tentative picture of why resistant cells may display impaired accumulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502–16.
Trédan P, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor micro-environment. J Natl Cancer Inst 2007;99:1441–54.
Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998;187:1583–98.
Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007;81:427–37.
Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007;6:31–6.
Hitt E. New platinum compound show promise. Lancet Oncol 2006;7:111.
Williams JW, Qu Y, Bulluss GH, Alvorado E, Farrell NP. Dinuclear platinum complexes with biological relevance based on the 1,2-diaminocyclohexane carrier ligand. Inorg Chem 2007;46:5820–2.
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227–35.
Fu S, Kavanagh JJ, Hu W, Bast Jr RC. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 2006;6:1717–32.
Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053–71.
Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003;3:21–9.
Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920–7.
Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087–90.
Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579–85.
Perego P, Caserini C, Gatti L, et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999;55:528–34.
O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006;27:682–92.
Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002;99:13963–5.
Katano K, Kondo A, Safei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559–65.
Chauhan SS, Liang XJ, Su AW, et al. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 2003;88:1327–34.
Beretta GL, Gatti L, Tinelli S, et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 2004;68:283–91.
Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol 2008;73:461–8.
Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006;70:1390–4.
Beretta GL, Benedetti V, Assaraf YGA, et al. Increased level and defective glycosylation of MRP4 contribute to reduced accumulation of oxaliplatin in ovarian carcinoma cells. Proceedings of the Pharmacology and Molecular Mechanisms Group 29th Winter meeting, Palermo, Italy, 30 January—2 February 2008, p. 53.
Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67:1171–6.
Martelli L, Di Mario F, Ragazzi E, et al. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 2006;72:693–700.
Huang Z, Tong Y, Wang J, Huang Y. NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells. Cancer Cell Int 2003;3:5.
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468–85.
Ishikawa,T, Kuo MT, Furuta K, Suzuki M. The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin Chem Lab Med. 2000;38:893–7.
Wielandt AM, Vollrath V, Manzano M, Miranda S, Accatino L, Chianale J. Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5-trichlorophenoxyacetic acid in the mouse liver. Biochem J 1999;341:105–11.
Oguri T, Isobe T, Suzuki T, et al. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 2000;86:95–100.
Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999;1461:359–76.
Borst P, Evers R, Kool M, Wijnhold JA. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295–1302.
Borst P, Kool M, Evers R. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin Cancer Biol 1997;8:205–13.
Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Met 1997;3:1275–9.
Takenaka K, Morgan, JA, Scheffer GL, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 2007;67:6965–72.
Materna V, Holm PS, Dietel M, Lage H. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2. Cancer Gene Ther 2001;8:176–84.
Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929–37.
Hinoshita E, Uchiumi T, Taguchi K, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 2000;6:2401–7.
Lanzi C, Perego P, Supino R, et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998;55:1247–54.
Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 2003;63:5909–16.
Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 2002;136:829–36.
Zhang S, Levejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxali-platin cytotoxicity. Cancer Res 2006;66:8847–57.
Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005;167:1477–84.
Daubeuf S, Leroy P, Paolicchi A, et al. Enhanced resistance of HeLa cells to cisplatin by overexpression of γ-glutamyltransferase. Biochem Pharmacol 2002;64:207–16.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gatti, L., Perego, P. (2009). Cellular Resistance to Oxaliplatin and Drug Accumulation Defects. In: Bonetti, A., Leone, R., Muggia, F.M., Howell, S.B. (eds) Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-459-3_16
Download citation
DOI: https://doi.org/10.1007/978-1-60327-459-3_16
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-458-6
Online ISBN: 978-1-60327-459-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)